Lupus Science & Medicine® is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. An official journal of the Lupus Foundation of America (LFA), which is dedicated to advancing the science and medicine of lupus while offering support to ...

Jul 26, 2024 · Objective To obtain updated estimates on the incidence and prevalence of systemic lupus erythematosus (SLE) in the UK, over the period 1990–2020, using the Clinical Practice Research Datalink (CPRD).Methods This was a retrospective cohort study using the CPRD covering the period 1990–2020. A case ascertainment algorithm was developed in line with best practice recommendations for ...

LiH, et≤al Lupus Science Medicine 202512e001400 doi101136lupus-2024-001400 1 Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis Huqun Li,1 Wenlong Xie,1 Chongshu Wang,2 Cuilian Guo 2 To cite: Li H, Xie W, Wang C, et al.Postmarketing safety evaluation of belimumab: a

AdelhelmfiBH, etfial Lupus Science Medicine 202310e001018 doi101136lupus2023001018 1 Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of

Jan 4, 2025 · Objective Black people in the USA have a higher incidence and severity of SLE and worse outcomes, yet they are significantly under-represented in SLE clinical trials. We assessed racial differences in clinical trial perceptions among a large cohort of predominantly Black people with SLE.Methods Georgians Organised Against Lupus (GOAL) is a population-based, prospective cohort of people with a ...

Jan 18, 2025 · Objectives Even in a lupus low disease activity state (LLDAS), many patients with SLE continue to face residual symptoms and disease burden. We aimed to evaluate the quality of life, activity impairment and overall work productivity impairment among patients in LLDAS. Residual disease burden was also evaluated for patients in LLDAS.Methods This prospective, cross-sectional study enrolled ...

Sep 5, 2024 · Hemophagocytic lymphohistiocytosis (HLH) is a well-recognised complication of systemic lupus erythematosus (SLE). In one small case series, HLH was noted in approximately 5% of patients with lupus. 1 Differentiating lupus flare from HLH can be challenging, since both can cause fever and cytopenia. A recent review of published literature included studies that combined information about a total ...

Hunnicuttfi, et≤al Lupus Science Medicine 202411e001206 doi101136lupus-2024-001206 1 Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ

Nordmann-GomesfiA, etfial Lupus Science Medicine 202411:e001331 doi:101136lupus-2024-001331 1 Lupus nephritis randomised controlled trials: evidence gaps and under- represented groups Alberto Nordmann-Gomes ,1,2 Gabriel Cojuc-Konigsberg,3 Adriana Hernández-Andrade, 2 Valeria Navarro-Sánchez,2 Juan Carlos Ramírez-Sandoval,2 Brad Rovin ,4 Juan M Mejia-Vilet 2

Oct 25, 2018 · Several patterns of hair loss can occur in lupus erythematosus (LE). Alopecias which show histological characteristics of LE are LE-specific, and include discoid LE (DLE), diffuse or patchy hair loss in acute LE, subacute cutaneous LE, and rarely tumid LE. Lupus hair in SLE is a poorly characterised entity and may be a form of telogen effluvium. Alopecia areata can coexist with LE and may ...